Holen Sie sich die Stockscreener-App
781.60
2.86%
21.74
Vorhandelsmarkt:
779.60
-2.00
-0.26%
Schlusskurs vom Vortag:
$759.86
Offen:
$759.86
24-Stunden-Volumen:
696.87K
Relative Volume:
0.85
Marktkapitalisierung:
$82.63B
Einnahmen:
$14.34B
Nettoeinkommen (Verlust:
$4.50B
KGV:
18.81
EPS:
41.5626
Netto-Cashflow:
$3.77B
1W Leistung:
-1.16%
1M Leistung:
+0.17%
6M Leistung:
+40.44%
1J Leistung:
+10.47%
1-Tages-Spanne:
$754.91
$783.70
1-Wochen-Bereich:
$746.66
$794.77
52-Wochen-Spanne:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Firmenname
Regeneron Pharmaceuticals Inc
Sektor
Branche
Telefon
(914) 847-7000
Adresse
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
781.60 | 80.33B | 14.34B | 4.50B | 3.77B | 41.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.87 | 116.01B | 12.07B | 3.95B | 3.19B | 15.33 |
|
ARGX
Argen X Se Adr
|
740.40 | 44.42B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.59 | 42.53B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
302.29 | 33.32B | 5.36B | 287.73M | 924.18M | 2.5229 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-06 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Hochstufung | BofA Securities | Underperform → Buy |
| 2025-12-03 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Eingeleitet | HSBC Securities | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-14 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Herabstufung | Argus | Buy → Hold |
| 2025-05-30 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-09-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Eingeleitet | Bernstein | Outperform |
| 2024-01-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Bestätigt | Oppenheimer | Perform |
| 2023-06-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-23 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2023-01-20 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-09-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-12-07 | Fortgesetzt | Cowen | Market Perform |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2021-11-05 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-01-25 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-10-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Hochstufung | SunTrust | Hold → Buy |
| 2020-05-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-17 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Eingeleitet | The Benchmark Company | Hold |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-11 | Hochstufung | Argus | Hold → Buy |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-16 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Hold |
| 2019-11-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
Alle ansehen
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Cowen Maintains Buy on Regeneron Pharmaceuticals, Inc. (REGN) March 2026 - Meyka
Regeneron's GLP-1/GIP obesity drug succeeds in late-stage trial - TechTarget
Pfizer Tries Again In Atopic Dermatitis, This Time With A Trispecific - Citeline News & Insights
Regeneron’s Weight Loss Partner Hansoh Delivers Much-Needed Phase 3 Win in China - BioSpace
Regeneron (REGN) Reports Positive Phase 3 Results for Obesity Dr - GuruFocus
Sienna Gestion Sells 9,627 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron-licensed obesity drug shows positive phase 3 results in China (REGN:NASDAQ) - Seeking Alpha
Vinva Investment Management Ltd Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron (REGN) Advances in Obesity Treatment with Promising Tr - GuruFocus
Olatorepatide obesity treatment licensed by Regeneron demonstrates positive phase 3 results in Chinese patients - marketscreener.com
Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients - The Manila Times
Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in ... - bdtonline.com
Jefferies Financial Group Inc. Acquires Shares of 25,535 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Natixis Advisors LLC Acquires 7,084 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by First Trust Advisors LP - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Victory Capital Management Inc. - MarketBeat
Pinnacle Associates Ltd. Has $47.34 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Prevail Innovative Wealth Advisors LLC Acquires Shares of 7,628 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Rhenman & Partners Asset Management AB - MarketBeat
Grantham Mayo Van Otterloo & Co. LLC Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Lowered to "Hold" Rating by Wall Street Zen - MarketBeat
Dimensional Fund Advisors LP Sells 20,341 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Barclays PLC Sells 157,105 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Illumina Regeneron Alliance Targets Multiomics And Raises Valuation Questions - Yahoo Finance UK
Assessing Regeneron Pharmaceuticals (REGN) Valuation As Shares Trade Below Estimated Fair Value - simplywall.st
Is Regeneron (REGN) Still Attractively Priced After Mixed Recent Share Performance - Yahoo Finance
Barclays Begins Coverage on Regeneron Pharmaceuticals (NASDAQ:REGN) - MarketBeat
Breaking Down Regeneron Pharmaceuticals: 14 Analysts Share Their Views - Benzinga
Here Are Friday’s Top Wall Street Analyst Research Calls: BorgWarner, CoreWeave, Intuit, Marvell Technology, Netflix, Okta, Regeneron Pharmaceuticals, Trade Desk, and More - 24/7 Wall St.
Picton Mahoney Asset Management Acquires 8,234 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
P/E Ratio Insights for Regeneron Pharmaceuticals - Sahm
Barclays initiates Regeneron stock with Overweight on Dupixent growth - Investing.com
Focus Partners Advisor Solutions LLC Acquires Shares of 2,909 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - AOL.com
Regeneron Announces Investor Conference Presentation - The Manila Times
Is Regeneron Pharmaceuticals (REGN) Offering Value After Recent Share Price Gains? - simplywall.st
(REGN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Myopic Macular Degeneration Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight Evaluates | Roche, Bayer, Regeneron Pharma - Barchart.com
Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies - AOL.com
Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering - Yahoo Finance
2 Biotech Giants to Buy in 2026 - AOL.com
2 Biotech Giants to Buy in 2026 - The Motley Fool
USA Herald - USA Herald
Skeletal Dysplasia Market - GlobeNewswire Inc.
Regeneron Pharmaceuticals Hits Day Low Amid Price Pressure at $764.49 - Markets Mojo
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Amova Asset Management Americas Inc. - MarketBeat
Regeneron, Sanofi Didn't Warn About Cancer Risk, Suit Says - Law360
Regeneron at TD Cowen Conference: Strategic Growth Insights - Investing.com
Bayer Q4 Earnings Match Estimates, Xarelto and Eylea Pull Down Sales - Finviz
Jim Cramer Says "I Should Have Pulled the Trigger on Regeneron" - Finviz
Jim Cramer Says “I Should Have Pulled the Trigger on Regeneron” - Insider Monkey
Finanzdaten der Regeneron Pharmaceuticals Inc-Aktie (REGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):